NRF2 Hits the News!
The National Cancer Institute Cancer Therapy Evaluation Program JUST approved the University of Texas MD Anderson Cancer Center to start clinical research of the Nrf2 pathway this month.
THE STUDY: “A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors”
What does that mean?… Read the rest